The State of the Art in the Development of Biosimilars

被引:116
|
作者
McCamish, Mark [2 ]
Woollett, Gillian [1 ]
机构
[1] Avalere Hlth, Washington, DC USA
[2] Sandoz Int, Global Biopharmaceut Dev, Holzkirchen, Germany
关键词
D O I
10.1038/clpt.2011.343
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The development of biologic therapeutics using advanced technology to copy and improve on nature's design of complex peptides, proteins, and glycoproteins has enabled the treatment of diseases in entirely new ways and brought unique and lifesaving treatments to many people. However, at least in part because of cost pressures, access to these truly amazing products has not been uniformly available; many patients do not qualify for these treatments, or the treatment is postponed until disabilities accumulate. The development of biosimilars essentially copies of the original biologic drugs after patent expiration allows for wider and, as important, earlier access to these agents because of their lower cost and consequently greater affordability. The development and commercialization of biosimilars can help address unmet medical needs by improving access to well-established therapeutic interventions while improving healthcare affordability.
引用
收藏
页码:405 / 417
页数:13
相关论文
共 50 条
  • [2] Development of biosimilars
    AL-Sabbagh, Ahmad
    Olech, Ewa
    McClellan, Joseph E.
    Kirchhoff, Carol F.
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2016, 45 (05) : S11 - S18
  • [3] Development of biosimilars
    Schellekens, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S70 - S70
  • [4] Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars
    Diaz, Luis Perez
    Millan, Susana
    Chaban, Nuran
    Campo, Ana del
    Spitzer, Eduardo
    [J]. FUTURE ONCOLOGY, 2021, 17 (19) : 2529 - 2544
  • [5] EXTRUSION STATE OF THE ART AND DEVELOPMENT
    BAUSER, M
    TUSCHY, E
    [J]. ZEITSCHRIFT FUR METALLKUNDE, 1982, 73 (07): : 411 - 419
  • [6] State of the art: Development of methods
    Brown, Nigel
    [J]. TOXICOLOGY LETTERS, 2009, 189 : S53 - S53
  • [7] State of the art in adrenal development
    Hanley, Neil A.
    [J]. ENDOCRINE JOURNAL, 2010, 57 : S309 - S309
  • [8] An Efficient Development Paradigm for Biosimilars
    Webster, Christopher J.
    Wong, Anny C.
    Woollett, Gillian R.
    [J]. BIODRUGS, 2019, 33 (06) : 603 - 611
  • [9] Development and Commercialization of Biosimilars in India
    Rathore, Anurag S.
    [J]. BIOPHARM INTERNATIONAL, 2011, 24 (11) : 36 - 40
  • [10] An Efficient Development Paradigm for Biosimilars
    Christopher J. Webster
    Anny C. Wong
    Gillian R. Woollett
    [J]. BioDrugs, 2019, 33 : 603 - 611